Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene Hugo description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX
Showing element 2058 to 2107 of 3228 in total
Value Type: Ranked
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2058\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
sh3 domain-binding glutamic acid-rich-like protein 2 (fovea-associated sh3 domain binding protein). [source:swissprot;acc:q9ujc5]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
218.79\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
216.981\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00834\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2059\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NCOA7\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nuclear receptor coactivator 7; estrogen receptor associated protein 140 kda. [source:refseq;acc:nm\_181782]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2060\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
C20orf118\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dj132f21.2 (contains a novel protein similar to the l82e from drosophila) (fragment). [source:sptrembl;acc:q9h125]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2061\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TBC1D22B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tbc1 domain family protein c22orf4-like (fragment). [source:swissprot;acc:q9nu19]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2062\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TBC1D22A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tbc1 domain family protein c22orf4. [source:swissprot;acc:q8wua7]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2063\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ODC1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ornithine decarboxylase (ec 4.1.1.17) (odc). [source:swissprot;acc:p11926]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.638\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.923\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00833\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2064\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AASS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
aminoadipate-semialdehyde synthase; lysine-ketoglutarate reductase /saccharopine dehydrogenase; lysine-2-oxoglutarate reductase; aminoadipic semialdehyde synthase. [source:refseq;acc:nm\_005763]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.655\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.939\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2065\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBE2N\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ubiquitin-conjugating enzyme e2 n (ec 6.3.2.19) (ubiquitin-protein ligase n) (ubiquitin carrier protein n) (ubc13) (bendless-like ubiquitin conjugating enzyme). [source:swissprot;acc:q16781]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
214.328\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
212.561\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00831\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2066\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PCNA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
proliferating cell nuclear antigen (pcna) (cyclin). [source:swissprot;acc:p12004]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
229.102\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
231.001\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00829\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2067\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADSL\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
adenylosuccinate lyase (ec 4.3.2.2) (adenylosuccinase) (asl) (asase). [source:swissprot;acc:p30566]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
193.226\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
191.639\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00828\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2068\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FAIM\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
fas apoptotic inhibitory molecule. [source:refseq;acc:nm\_018147]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
220.8\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
222.61\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0082\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2069\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAP2K1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 1 (ec 2.7.1.-) (map kinase kinase 1) (mapkk 1) (erk activator kinase 1) (mapk/erk kinase 1) (mek1). [source:swissprot;acc:q02750]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.555\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
215.807\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.0081\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2070\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RACGAP1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
rac gtpase activating protein 1; gtpase activating protein. [source:refseq;acc:nm\_013277]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
223.199\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
225.008\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2071\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KSR1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
similar to kinase suppressor of ras (fragment). [source:sptrembl;acc:q8ivt5]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
217.555\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
215.807\vspace{3pt}}}&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2072\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAP2K2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 2 (ec 2.7.1.-) (map kinase kinase 2) (mapkk 2) (erk activator kinase 2) (mapk/erk kinase 2) (mek2). [source:swissprot;acc:p36507]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2073\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PAPD5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
topoisomerase-related function protein 4-2. [source:refseq;acc:nm\_022447]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
229.267\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
227.433\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00806\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2074\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POLG\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dna polymerase gamma subunit 1 (ec 2.7.7.7) (mitochondrial dna polymerase catalytic subunit) (polg-alpha). [source:swissprot;acc:p54098]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.324\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
214.599\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00804\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2075\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CD109\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cd109; gov system alloantigens on platelets. [source:refseq;acc:nm\_133493]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
221.703\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
223.483\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00803\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2076\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PIN1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
peptidyl-prolyl cis-trans isomerase nima-interacting 1 (ec 5.2.1.8) (rotamase pin1) (ppiase pin1). [source:swissprot;acc:q13526]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2077\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
IRX4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
iroquois-class homeodomain protein irx-4 (iroquois homeobox protein 4). [source:swissprot;acc:p78413]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2078\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FIGNL1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
fidgetin-like 1. [source:refseq;acc:nm\_022116]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.511\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
213.814\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00794\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2079\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PIK3C2G\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
phosphatidylinositol-4-phosphate 3-kinase c2 domain-containing gamma polypeptide (ec 2.7.1.154) (phosphoinositide 3-kinase-c2-gamma) (ptdins-3-kinase c2 gamma) (pi3k-c2gamma). [source:swissprot;acc:o75747]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
215.967\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
214.28\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00787\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2080\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PIK3C2B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
phosphatidylinositol-4-phosphate 3-kinase c2 domain-containing beta polypeptide (ec 2.7.1.154) (phosphoinositide 3-kinase-c2-beta) (ptdins-3-kinase c2 beta) (pi3k-c2beta) (c2-pi3k). [source:swissprot;acc:o00750]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2081\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNM1L\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dynamin 1-like protein isoform 3; dynamin-like protein. [source:refseq;acc:nm\_005690]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2082\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PIK3C2A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
phosphoinositide-3-kinase, class 2, alpha polypeptide; c2-containing phosphatidylinositol kinase. [source:refseq;acc:nm\_002645]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2083\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PTPRA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vacuolar protein sorting 16 (hvps16). [source:swissprot;acc:q9h269]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.258\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
213.579\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00786\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2084\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 1 (ec 2.6.1.16) (hexosephosphate aminotransferase 1) (d-fructose-6- phosphate amidotransferase 1) (gfat 1) (gfat1). [source:swissprot;acc:q06210]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
222.548\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
224.293\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00784\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2085\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
IDH3A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
isocitrate dehydrogenase [nad] subunit alpha, mitochondrial precursor (ec 1.1.1.41) (isocitric dehydrogenase) (nad+-specific icdh). [source:swissprot;acc:p50213]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
222.58\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
224.32\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00782\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2086\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
IDH3B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
isocitrate dehydrogenase [nad] subunit beta, mitochondrial precursor (ec 1.1.1.41) (isocitric dehydrogenase) (nad+-specific icdh). [source:swissprot;acc:o43837]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2087\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
IDH3G\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
isocitrate dehydrogenase [nad] subunit gamma, mitochondrial precursor (ec 1.1.1.41) (isocitric dehydrogenase) (nad+-specific icdh). [source:swissprot;acc:p51553]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2088\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MPP3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
maguk p55 subfamily member 3 (mpp3 protein) (discs, large homolog 3). [source:swissprot;acc:q13368]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
218.124\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
216.433\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00781\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2089\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UTP14A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
serologically defined colon cancer antigen 16. [source:refseq;acc:nm\_006649]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.144\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
213.479\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0078\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2090\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GFPT2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 2 (ec 2.6.1.16) (hexosephosphate aminotransferase 2) (d-fructose-6- phosphate amidotransferase 2) (gfat 2) (gfat2). [source:swissprot;acc:o94808]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
222.609\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
224.344\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00779\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2091\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SNUPN\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
rna, u transporter 1; snurportin-1. [source:refseq;acc:nm\_005701]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
211.679\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.052\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00775\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2092\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ECSIT\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
evolutionarily conserved signaling intermediate in toll pathway; ecsit. [source:refseq;acc:nm\_016581]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
211.992\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.369\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00772\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2093\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RBKS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ribokinase (ec 2.7.1.15). [source:swissprot;acc:q9h477]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
209.994\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
208.387\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00771\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2094\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PMS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
pms1 protein homolog 2 (dna mismatch repair protein pms2). [source:swissprot;acc:p54278]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.321\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.747\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00765\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2095\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POLS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
polymerase (dna directed) sigma; topoisomerase-related function protein 4-1; polymerase (dna-directed) sigma. [source:refseq;acc:nm\_006999]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
229.266\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
227.53\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00763\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2096\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CCDC92\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
limkain beta 2. [source:refseq;acc:nm\_025140]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.723\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
216.089\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00756\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2097\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CCDC85B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
delta-interacting protein a (hepatitis delta antigen interacting protein a). [source:swissprot;acc:q15834]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
214.979\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
213.39\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00745\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2098\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ret finger protein 2 (leukemia associated protein 5) (b-cell chronic lymphocytic leukemia tumor suppressor leu5) (putative tumor suppressor rfp2) (tripartite motif protein 13). [source:swissprot;acc:o60858]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
177.515\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
178.831\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00741\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2099\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SUMO3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ubiquitin-like protein smt3a. [source:swissprot;acc:p55854]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
211.71\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
213.27\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00737\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2100\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ubiquitin-like protein smt3b (sentrin 2) (hsmt3). [source:swissprot;acc:p55855]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2101\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ACRC\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
acrc protein; putative nuclear protein. [source:refseq;acc:nm\_052957]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2102\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EIF5AP1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
eukaryotic translation initiation factor 5a (eif-5a) (eif-4d) (rev- binding factor). [source:swissprot;acc:p10159]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
208.727\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.263\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00736\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2103\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TKT\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
transketolase (ec 2.2.1.1) (tk). [source:swissprot;acc:p29401]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
214.666\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
216.236\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00731\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2104\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DTYMK\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
thymidylate kinase (ec 2.7.4.9) (dtmp kinase). [source:swissprot;acc:p23919]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
209.328\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.813\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00729\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2105\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EIF5A2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
eif-5a2 protein. [source:refseq;acc:nm\_020390]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
208.591\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.111\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2106\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ISL1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
insulin gene enhancer protein isl-1 (islet-1). [source:swissprot;acc:p20663]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
197.489\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
196.061\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00728\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2107\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LMO7\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
lim domain only 7; zinc-finger domain-containing protein; lomp protein; f-box only protein 20; f-box protein fbx20. [source:refseq;acc:nm\_005358]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.23\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
217.801\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00727\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the HGNC identifier if it exists

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/